跳至主要内容
临床试验/NCT01246713
NCT01246713已完成不适用

Effect on Acetaminophen Metabolism by Liquid Formulations: Do Excipients in Liquid Formulation Prevent Production of Toxic Metabolites?

Beth Israel Deaconess Medical Center1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
15
试验地点
1
主要终点
Acetaminophen Metabolites

研究概览

简要总结

The purpose of this study is to determine whether excipients in the liquid formulation of acetaminophen prevent the formation of the toxic metabolites of acetaminophen.

详细描述

Acetaminophen (APAP) poisoning is the most frequent cause of acute hepatic failure in the United States. Toxicity requires cytochrome P-450 bioactivation of APAP. Children are less susceptible to APAP toxicity; the current theory is that they have different metabolism than adults. However, children's liquid preparations of APAP contain excipients which have been shown to inhibit APAP bioactivation in vitro and in rodents. Children tend to ingest liquid preparations, which could potentially explain their decreased susceptibility instead of an intrinsically different metabolism. Further, our review of Poison Center epidemiologic data shows that liquid preparations are less toxic in adults. Our hypothesis is that excipients in liquid preparations inhibit the bioactivation of APAP. The design is a pharmacokinetic cross-over study in humans. Healthy adult subjects will be recruited for administration of therapeutic doses of APAP in capsule and liquid formulations. Plasma via a heplock will be collected at serial time points up to 8 hours and assayed for APAP and its metabolites. After a washout period, subjects will receive the same dose of APAP in the alternate preparation. The pattern of metabolites, indicating the activity of the bioactivating enzymes, will be compared. A significant difference in P-450 metabolites will support the hypothesis and provide preliminary data for studies in patients who have ingested potentially toxic doses of APAP. Ultimately, this work could support development of novel antidotal therapy for APAP overdose.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteer ages 18-40
  • Not taking any chronic medications

排除标准

  • Pregnancy
  • Any history of liver disease
  • Frequent alcohol use (2 or more drinks more than 4 times per week)
  • Unable to provide informed consent

研究组 & 干预措施

Acetaminophen solid formulation

Placebo Comparator

Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.

干预措施: Acetaminophen solid formulation (Drug)

Acetaminophen liquid formulation

Active Comparator

Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.

干预措施: Acetaminophen liquid formulation (Drug)

结局指标

主要结局

Acetaminophen Metabolites

时间窗: 8 hours

Area-under-curve from time zero to 8 hours for APAP-cysteinate metabolite. Serum was collected just prior to and at hours 1, 2, 4, 6, and 8 after administration of the APAP dose.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Michael Ganetsky

Assistant Professor of Emergency Medicine

Beth Israel Deaconess Medical Center

研究点 (1)

Loading locations...

相似试验